XPH Looks Tempting, but the Five-Year Chart Warns Investors
SPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...
Index level analysis helps pinpoint trend direction. This concise guide offers practical steps to identify and follow the prevailing trend.
20,971 articlesSPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...
European ministers press Washington for clear goals as talks on a naval coalition to secure Gulf shipping falter, rai...
A Fortune interview reveals that Trump’s leadership model succession may not be transferrable, prompting investors an...
When volatility hits, a market correction can unlock discount opportunities in broad ETFs. Learn how to use this mome...
Morgan Stanley argues that a selective rotation is underway as the chip pullback ushering bumpy market reshapes leade...
Booking Holdings trades at elevated levels, reigniting debate over whether a stock split could broaden retail ownersh...
A growing wave of funds aims to turn congressional stock disclosures into tradable signals, but investors face questi...
A new northwestern mutual 2025 study exposes a sharp mismatch: Millennials prize wealth transfer yet most have not se...
NUKZ is in focus as two pivotal drivers could redefine its trajectory: big-hyperscaler nuclear agreements and the rol...
As Brazil begins a measured rate-cut cycle, EWZ may emerge as a tactical edge in 2026. A slower Fed and a stronger BR...
A simple, time-tested approach often beats chasing hot sectors. Learn why a broad-market ETF could be your winning mo...
These software stocks have surged as geopolitical tensions rise, outpacing broader tech gains and signaling a shift i...